AKT1 and COVID-19: PI3K inhibitors can alleviate pulmonary edema in mice and significantly alleviate pulmonary inflammatory response, suggesting that the core compound in SHXP may alleviate pulmonary inflammation in patients with COVID-19 by controlling the PI3K-Akt signaling pathway.[63] Besides, HIF-1 signaling pathway, TNF signaling pathway, IL-17 signaling pathway, T cell receptor signaling pathway and other signaling pathways are also enriched in hub genes, which may be related to the effect of SHXP on COVID-19.